Tech was leading the way lower for stocks Wednesday. BTIG Chief Market Technician Jonathan Krinsky noted that while tech ...

Tech-sector weakness was threatening to leave some investors with heartburn over the Thanksgiving holiday. It isn’t all bad ...

After adding nearly 30% in the previous session following its better-than-expected Q4 results for FY24, Embecta (NASDAQ:EMBC) ...

BTIG analyst Michael Gorman raised the firm’s price target on Agree Realty (ADC) to $78 from $74 and keeps a Buy rating on the shares. Agree ...

BTIG lowered the firm’s price target on Pinstripes (PNST) to $3 from $4 and keeps a Buy rating on the shares. Pinstripes reported another weak quarter, capping off a difficult first half of the fiscal ...

Investors should start looking at restaurant names that have timely setups, said Jonathan Krinsky, chief market technician at ...

However, with Donald Trump's recent presidential victory, there are signs of a potential shift. BTIG has highlighted an ...

BTIG analyst Andrew Harte is praising MicroStrategy's (NASDAQ:MSTR) plan announced at the end of October to raise $42B of ...

Alector (NASDAQ:ALEC – Free Report) had its target price lowered by BTIG Research from $16.00 to $5.00 in a research note ...

STAAR Surgical Company (NASDAQ: STAA), a leading developer, manufacturer and marketer of the EVO family of Implantable ...

BTIG upgraded Aclaris Therapeutics (ACRS) to Buy from Neutral with an $8 price target In a “transformative transaction,” Aclaris has acquired full ex-China rights to an anti-TSLP humanized mAb and ...